Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 19/20 | 0.80 |
| ▸ | NOTCH3 | Q9UM47 | 17/20 | 0.80 |
| ▸ | NOTCH2 | Q04721 | 1/20 | 0.80 |
| ▸ | NOTCH4 | Q99466 | 1/20 | 0.80 |
| ▸ | RBPJ | Q06330 | 2/20 | 0.70 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.70 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.70 |
| ▸ | CCKBR | P32239 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osugacestat SCHEMBL21577519 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL12543867 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL15622455 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL17420836 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL12543868 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL18288911 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| Osugacestat SCHEMBL29412689 | 0.97 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| SCHEMBL23665996 | 0.95 | NOTCH1 (0.81) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| SCHEMBL25901263 | 0.94 | NOTCH1 (0.88) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ | |
| SCHEMBL22660068 | 0.93 | NOTCH1 (0.83) | NOTCH1NOTCH3NOTCH2NOTCH4RBPJ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381196-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA | AYALA PHARMACEUTICALS INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210220372-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210040050-A1 | COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4- BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | AYALA PHARMACEUTICALS INC. (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2021024191-A2 | COMBINATION TREATMENTS WITH BENZODIAZEPINONE COMPOUNDS AND PHOSPHOINOSITIDE 3-KINASE PATHWAY INHIBITORS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220372-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | CYP2F1, CYP2C19, CYP3A7 | NOTCH1 3122/4885NOTCH3 4090/4885NOTCH2 4459/4885 |
| US-20230381196-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA | AKR1C3, AKR1D1, CYP2C19 | NOTCH1 3781/4885NOTCH3 4248/4885NOTCH2 4683/4885 |
| US-20210040050-A1 | COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4- BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | CYP2C19, CYP2F1, CYP3A7 | NOTCH1 3152/4885NOTCH3 4042/4885NOTCH2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.